Novartis Ag (NVS) Minority Interest (2009 - 2025)
Novartis Ag recorded quarterly Minority Interest of $419.0 million in Q4 2025, down 0.71% quarter-over-quarter from $422.0 million in Q3 2025, and up 423.75% year-over-year from $80.0 million in Q4 2024.
Novartis Ag's Minority Interest history runs 17 years deep, the most recent figure standing at $419.0 million for Q4 2025.
- In Q4 2025, Minority Interest rose 423.75% year-over-year to $419.0 million; the TTM figure through Dec 2025 stood at $419.0 million (up 423.75% YoY), while the FY2025 annual figure was $419.0 million, up 423.75% from the prior year.
- Minority Interest came in at $419.0 million for Q4 2025 at Novartis Ag, down from $422.0 million in the prior quarter.
- In the past five years, Minority Interest ranged from a high of $422.0 million in Q3 2025 to a low of -$17.0 million in Q2 2025.
- A 5-year average of $101.8 million and a median of $81.0 million in 2022 frame the typical range for Minority Interest.
- Across the five-year window, Minority Interest tumbled 200.0% in 2024 and soared 10650.0% in 2025, its largest moves.
- Novartis Ag's Minority Interest stood at $167.0 million in 2021, then slumped by 51.5% to $81.0 million in 2022, then climbed by 2.47% to $83.0 million in 2023, then slipped by 3.61% to $80.0 million in 2024, then surged by 423.75% to $419.0 million in 2025.
- According to Business Quant data, Minority Interest over the past three periods registered $419.0 million, $422.0 million, and -$17.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 419.00 Mn |
| Sep 30, 2025 | 422.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 80.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Dec 31, 2023 | 83.00 Mn |
| Sep 30, 2023 | 4.00 Mn |
| Jun 30, 2023 | 84.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 81.00 Mn |
| Sep 30, 2022 | 78.00 Mn |
| Jun 30, 2022 | 81.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | 167.00 Mn |
| Sep 30, 2021 | 166.00 Mn |
| Jun 30, 2021 | 86.00 Mn |
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | -6.00 Mn |
| Jun 30, 2020 | 3.00 Mn |
| Mar 31, 2020 | -3.00 Mn |
| Dec 31, 2019 | 77.00 Mn |
| Sep 30, 2019 | 74.00 Mn |
| Jun 30, 2019 | 78.00 Mn |
| Mar 31, 2019 | 78.00 Mn |
| Dec 31, 2018 | 78.00 Mn |
| Sep 30, 2018 | 81.00 Mn |
| Jun 30, 2018 | 86.00 Mn |
| Mar 31, 2018 | 3.00 Mn |
| Sep 30, 2017 | 59.00 Mn |
| Jun 30, 2017 | 59.00 Mn |
| Mar 31, 2017 | -1.00 Mn |
| Dec 31, 2016 | -21.00 Mn |
| Sep 30, 2016 | 82.00 Mn |
| Jun 30, 2016 | 76.00 |
| Dec 31, 2015 | 11.00 Mn |
| Sep 30, 2015 | 9.00 Mn |
| Jun 30, 2015 | 2.00 |
| Mar 31, 2015 | 68.00 |
| Dec 31, 2014 | 70.00 Mn |
| Sep 30, 2014 | 74.00 |
| Jun 30, 2014 | 30.00 |
| Mar 31, 2014 | 27.00 |
| Dec 31, 2013 | 117.00 |
| Sep 30, 2013 | 132.00 |
| Jun 30, 2013 | 135.00 |
| Mar 31, 2013 | 119.00 |
| Sep 30, 2012 | 123.00 |
| Jun 30, 2012 | 111.00 |
| Mar 31, 2012 | 22.00 |
| Dec 31, 2011 | 96.00 |
| Sep 30, 2011 | 97.00 |
| Jun 30, 2011 | 22.00 |
| Mar 31, 2011 | 51.00 |
| Dec 31, 2010 | 175.00 |
| Sep 30, 2010 | 79.00 |
| Jun 30, 2010 | 20.00 |
| Mar 31, 2010 | 15.00 |
| Dec 31, 2009 | 54.00 |
| Sep 30, 2009 | 36.00 |
| Jun 30, 2009 | 9.00 |
| Mar 31, 2009 | 13.00 |